206 related articles for article (PubMed ID: 24330732)
21. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
Rong Y; Belozerov VE; Tucker-Burden C; Chen G; Durden DL; Olson JJ; Van Meir EG; Mackman N; Brat DJ
Cancer Res; 2009 Mar; 69(6):2540-9. PubMed ID: 19276385
[TBL] [Abstract][Full Text] [Related]
22. Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling.
McNulty SN; Cottrell CE; Vigh-Conrad KA; Carter JH; Heusel JW; Ansstas G; Dahiya S
Hum Pathol; 2019 Apr; 86():170-181. PubMed ID: 30594748
[TBL] [Abstract][Full Text] [Related]
23. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults.
Jha P; Suri V; Singh G; Jha P; Purkait S; Pathak P; Sharma V; Sharma MC; Suri A; Gupta D; Mahapatra AK; Sarkar C
Diagn Mol Pathol; 2011 Dec; 20(4):225-32. PubMed ID: 22089350
[TBL] [Abstract][Full Text] [Related]
24. A survey of glioblastoma genomic amplifications and deletions.
Rao SK; Edwards J; Joshi AD; Siu IM; Riggins GJ
J Neurooncol; 2010 Jan; 96(2):169-79. PubMed ID: 19609742
[TBL] [Abstract][Full Text] [Related]
25. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
[TBL] [Abstract][Full Text] [Related]
26. Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development.
Koga T; Li B; Figueroa JM; Ren B; Chen CC; Carter BS; Furnari FB
Neuro Oncol; 2018 Sep; 20(10):1310-1320. PubMed ID: 29660021
[TBL] [Abstract][Full Text] [Related]
27. Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history.
Furukawa M; Soh J; Yamamoto H; Ichimura K; Shien K; Maki Y; Muraoka T; Tanaka N; Ueno T; Asano H; Tsukuda K; Toyooka S; Miyoshi S
Acta Med Okayama; 2013; 67(1):19-24. PubMed ID: 23439505
[TBL] [Abstract][Full Text] [Related]
28. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
[TBL] [Abstract][Full Text] [Related]
29. Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma.
Muñoz-Hidalgo L; San-Miguel T; Megías J; Monleón D; Navarro L; Roldán P; Cerdá-Nicolás M; López-Ginés C
Neoplasia; 2020 Jan; 22(1):10-21. PubMed ID: 31751860
[TBL] [Abstract][Full Text] [Related]
30. Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma.
Higa N; Akahane T; Hamada T; Yonezawa H; Uchida H; Makino R; Watanabe S; Takajo T; Yokoyama S; Kirishima M; Matsuo K; Fujio S; Hanaya R; Tanimoto A; Yoshimoto K
Cancer Med; 2023 Jan; 12(1):49-60. PubMed ID: 35695190
[TBL] [Abstract][Full Text] [Related]
31. Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme?
Burger PC; Pearl DK; Aldape K; Yates AJ; Scheithauer BW; Passe SM; Jenkins RB; James CD
J Neuropathol Exp Neurol; 2001 Nov; 60(11):1099-104. PubMed ID: 11706939
[TBL] [Abstract][Full Text] [Related]
32. Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activation.
Furgason JM; Li W; Milholland B; Cross E; Li Y; McPherson CM; Warnick RE; Rixe O; Stambrook PJ; Vijg J; Bahassi el M
Mutagenesis; 2014 Sep; 29(5):341-50. PubMed ID: 25103728
[TBL] [Abstract][Full Text] [Related]
33. CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry.
Purkait S; Jha P; Sharma MC; Suri V; Sharma M; Kale SS; Sarkar C
Neuropathology; 2013 Aug; 33(4):405-12. PubMed ID: 23311918
[TBL] [Abstract][Full Text] [Related]
34. Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
Gilder AS; Jones KA; Hu J; Wang L; Chen CC; Carter BS; Gonias SL
J Biol Chem; 2015 Jun; 290(24):14798-809. PubMed ID: 25837250
[TBL] [Abstract][Full Text] [Related]
35. Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling.
Ruano Y; Mollejo M; Ribalta T; Fiaño C; Camacho FI; Gómez E; de Lope AR; Hernández-Moneo JL; Martínez P; Meléndez B
Mol Cancer; 2006 Sep; 5():39. PubMed ID: 17002787
[TBL] [Abstract][Full Text] [Related]
36. Alteration of major vault protein in human glioblastoma and its relation with EGFR and PTEN status.
Navarro L; Gil-Benso R; Megías J; Muñoz-Hidalgo L; San-Miguel T; Callaghan RC; González-Darder JM; López-Ginés C; Cerdá-Nicolás MJ
Neuroscience; 2015 Jun; 297():243-51. PubMed ID: 25869624
[TBL] [Abstract][Full Text] [Related]
37. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas.
Biernat W; Huang H; Yokoo H; Kleihues P; Ohgaki H
Brain Pathol; 2004 Apr; 14(2):131-6. PubMed ID: 15193025
[TBL] [Abstract][Full Text] [Related]
38. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival.
Das P; Puri T; Jha P; Pathak P; Joshi N; Suri V; Sharma MC; Sharma BS; Mahapatra AK; Suri A; Sarkar C
J Clin Neurosci; 2011 Jan; 18(1):66-70. PubMed ID: 20888234
[TBL] [Abstract][Full Text] [Related]
39. Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential.
Stockhausen MT; Kristoffersen K; Stobbe L; Poulsen HS
Cancer Biol Ther; 2014 Feb; 15(2):216-24. PubMed ID: 24525857
[TBL] [Abstract][Full Text] [Related]
40. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]